ERCC1 and Ki67 in Small Cell Lung Carcinoma and Other Neuroendocrine Tumors of the Lung: Distribution and Impact on Survival
- 1 April 2010
- journal article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 5 (4), 453-459
- https://doi.org/10.1097/jto.0b013e3181ca063b
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124Journal of Clinical Oncology, 2009
- Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA ExpressionPLOS ONE, 2009
- Excision Repair Cross Complementing-1 and Topoisomerase IIα Gene Expression in Small-Cell Lung Cancer Patients Treated with Platinum and Etoposide: A Retrospective StudyJournal of Thoracic Oncology, 2008
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung CancerJournal of Thoracic Oncology, 2007
- Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumorsEndocrine-Related Cancer, 2007
- Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancerLung Cancer, 2007
- Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancerAnnals Of Oncology, 2007
- Modern Management of Small-Cell Lung CancerDrugs, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2006